Denise Zamore - 12 Mar 2025 Form 3 Insider Report for agilon health, inc. (AGL)

Role
Chief Legal Officer
Signature
/s/ Mimi Yang, as Attorney-in-Fact
Issuer symbol
AGL
Transactions as of
12 Mar 2025
Transactions value $
$0
Form type
3
Filing time
24 Mar 2025, 18:49:54 UTC
Next filing
03 Apr 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding AGL Common Stock 204,948 12 Mar 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding AGL Options (Right to buy) 12 Mar 2025 Common Stock 18,983 $21.41 Direct F3
holding AGL Options (Right to buy) 12 Mar 2025 Common Stock 11,392 $28.46 Direct F4
holding AGL Options (Right to buy) 12 Mar 2025 Common Stock 115,314 $4.46 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes Performance Stock Units which may become vested subject to attainment (based on 40 trading day average closing price, exceeding twice the closing price of the Company's stock price on date of grant) and within three years from grant date.
F2 Includes restricted stock units.
F3 These options were granted on August 23, 2022, and vest in four equal installments on each anniversary of the grant date, subject to continued employment.
F4 These options were granted on April 14, 2023, and vest in four equal installments on each anniversary of the grant date, subject to continued employment.
F5 These options were granted on April 15, 2024, and vest in four equal installments on each anniversary of the grant date, subject to continued employment.

Remarks:

Exhibit List: Ex.24 - Power of Attorney